ArticleScientific data2015
Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes.
Article in Scientific data, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Conserved hepatic RNA signatures across multiple cohorts reveal novel mechanistic clues for advanced fibrosis in human MASLD.Hepatology communications · 2026Pooled it
- Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.Life science alliance · 2024Pooled it
- Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease.Nature communications · 2023Pooled it
- Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.Nature communications · 2026Article
- DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs.Frontiers in cell and developmental biology · 2026Article
- Identification of potential metabolic biomarkers and immune cell infiltration for metabolic associated steatohepatitis by bioinformatics analysis and machine learning.Scientific reports · 2025Article
- Circulating glycerate predicts resilience to fructose-induced hepatic steatosis.Cell metabolism · 2025Article
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma.Scientific reports · 2024Article
- The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis.Journal of translational medicine · 2022Article
- Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With Obesity.Hepatology communications · 2022Article
- Analysis of Differentially Expressed Genes That Aggravate Metabolic Diseases in Depression.Life (Basel, Switzerland) · 2021Article
- Defining NASH from a Multi-Omics Systems Biology Perspective.Journal of clinical medicine · 2021Review
- Article
- RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages.Cell death and differentiation · 2021Article
- A stem cell basedBiology open · 2021Article
- Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease.Frontiers in pharmacology · 2021Article
- Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis.Biochemistry and biophysics reports · 2020Article
- Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice.The Journal of clinical investigation · 2020Article
- Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease.Scientific reports · 2019Article
- Inhibition of Heme Oxygenase Antioxidant Activity Exacerbates Hepatic Steatosis and FibrosisAntioxidants (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 5 countries.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a consequence of sedentary life style and high fat diets with an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms within, e.g., APOC3, PNPLA3, NCAN, TM6SF2 and PPP1R3B, correlate with NAFLD. Several studies have already investigated later stages of the disease. This study explores the early steatosis stage of NAFLD with the aim of identifying molecular mechanisms underlying the etiology of NAFLD. We analyzed liver biopsies and serum samples from patients with high- and low-grade steatosis (also pre-disease states) employing transcriptomics, ELISA-based serum protein analyses and metabolomics. Here, we provide a detailed description of the various related datasets produced in the course of this study. These datasets may help other researchers find new clues for the etiology of NAFLD and the mechanisms underlying its progression to more severe disease states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.